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Medical cannabis is increasingly used as a treatment for chronic pain, and there is initial 
evidence that medical cannabis may lead to a subsequent decrease in prescription opioid use. The 
objective of the current study was to conduct a retrospective, naturalistic examination of medical 
cannabis use (i.e., dose, frequency, type) and subsequent changes in prescription opioid use 
among a sample of treatment-seeking chronic (non-cancer-related) pain patients (N =277). Data 
from the electronic medical record (EMR) was paired with information from the State 
Prescription Drug Monitoring Program and collected at time of initial certification and at six 
months post-certification. Results indicated that 91% of patients used their certification to buy 
medical cannabis at least once within the first six months. Heterogeneity in purchase patterns 
was observed (range of total doses purchased = 5 to 417, mean = 64.5, SD = 67). High THC:low 
CBD and vaporization-based products were the most common formulations purchased. A total of 
37% of all patients who purchased medical cannabis at least once evinced a clinically significant 
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Medical Cannabis Use among Chronic Pain Patients and Associations with Prescription Opioid 
Use: A Retrospective Study 
Chronic (non-cancer related) pain is a debilitating, critical national health problem that 
affects up to twenty percent of adults in the United States (Dahlhamer et al., 2018), with more 
than 25 million experiencing pain every day (Nahin, 2015). As a result, chronic pain accounts for 
nearly $600 billion annually in health care expenses and lost productivity (Gaskin & Richard, 
2012). Opioid-based pain medicines are a common treatment for chronic pain (Guy et al., 2017) 
and 2.9 million U.S. adults initiate long-term (> 3 months) opioid therapy each year (Boudreau et 
al., 2009). Rates of opioid prescriptions have fallen in recent years (CDC, 2019). However, 
chronic pain patients often receive high doses of prescription opioids for long periods of time 
(Boudreau et al., 2009; Von Korff et al., 2008), placing them at greater risk for opioid overdose 
and related problems (Bohnert et al., 2011; Edlund et al., 2014). For example, accidental opioid 
overdose is more common among individuals who are prescribed opioids for chronic pain (vs. 
illicit opioid use; Johnson et al., 2013). In response to these findings and the current opioid 
misuse epidemic, investigators have called for research into alternative pain management 
interventions (Mackey, 2016; Qaseem, Wilt, McLean, Forciea, & Clinical Guidelines Committee 
of the American College of, 2017). 
Cannabis-based medicines (CBMs) including medical cannabis are one promising 
approach to the management of chronic pain (Aviram & Samuelly-Leichtag, 2017; Gruber et al., 
2017) and may serve as an adjunct to prescription opioids (National Academies of Sciences, 
2017). The cannabis plant and has been used as an analgesic for at least 2,000 years (Pain, 2015), 
and a comprehensive review by the National Academy of Sciences concluded that there is 




Academies of Sciences, 2017). Cannabis appears to reduce pain by activating the 
endocannabinoid receptors and downregulating pain signaling in the central and peripheral 
nervous system (Woodhams, Sagar, Burston, & Chapman, 2015). Reductions in pain may also be 
a function of anti-inflammatory and mood-enhancing properties of specific cannabinoids 
(Woodhams et al., 2015).  
 The term medical cannabis has been used to reference prescription preparations of the 
cannabis plant for therapeutic purposes. Chronic pain is the most common self-reported reason 
that patients use medical cannabis (Kosiba et al., 2019), and severe or chronic pain is the most 
frequently condition cited for seeking a medical cannabis certification (Light, 2014; Troutt & 
DiDonato, 2015). Medical cannabis patients also report that the drug is highly efficacious for 
managing chronic pain. For example, approximately 83% of those who endorsed chronic pain 
indicated that their prescription resulted in “a lot or almost complete relief” of pain, among a 
sample of 367 medical cannabis dispensary visitors with chronic pain (Troutt & DiDonato, 
2015). A second study reported that 67% of 217 medical cannabis users in California described 
medical cannabis as beneficial for managing chronic pain (Bonn-Miller et al., 2014).  
Critical questions remain regarding the use of medical cannabis among chronic pain 
patients. First, research has only begun to characterize the frequency and type of medical 
cannabis used by chronic pain patients and little data is available among persons seeking initial 
certification (Boehnke, Scott, Litinas, Sisley, Clauw, et al., 2019; O'Connell, Sandgren, Frantzen, 
Bower, & Erickson, 2019). Indeed, up to 36% of certified patients may not purchase medical 
cannabis at all, thus negating possible therapeutic benefits (O'Connell et al., 2019; Zolotov, 
Baruch, Reuveni, & Magnezi, 2016). Furthermore, self-report of medical cannabis use has rarely 




predictors of use have not been examined. Addressing these questions is an essential step in 
understanding medical cannabis use and facilitating effective use among patients with chronic 
pain (Fischer et al., 2017a; Kahan, Srivastava, Spithoff, & Bromley, 2014).  
A second critical question is whether or not chronic pain patients reduce their use of 
prescription opioids after purchasing medical cannabis, thereby mitigating exposure to associated 
risks and side effects. Animal studies indicate that cannabis may exert an opioid-sparing effect 
via cannabinoid receptor activation (Chen et al., 2019; Cooper et al., 2018), and cross-sectional, 
self-report surveys indicate that up to 53% of medical cannabis users have substituted the drug 
for prescription opioids (Boehnke, Litinas, & Clauw, 2016; Boehnke, Scott, Litinas, Sisley, 
Williams, et al., 2019; Ishida et al., 2019; Lucas & Walsh, 2017). However, only two 
longitudinal studies have used medical record data to examine changes in prescription opioid use 
among chronic pain patients certified for medical cannabis (i.e., O'Connell et al., 2019; Vigil, 
Stith, Adams, & Reeve, 2017).  
Vigil et al. (2017) conducted a single-center, retrospective study among opioid-
maintained chronic pain patients enrolled in a medical cannabis program in New Mexico (N = 
29; 46% female, Mage = 54). Results indicated that medical cannabis re-certification (vs. no 
certification) was associated with greater odds of stopping opioid medications (OR = 17.3), and 
of reducing daily dosage of prescription opioids (OR = 5.1). However, this study was limited to 
patients seeking re-certification for medical cannabis, thus presenting a potential selection bias. 
O’Connell et al (2019) conducted a single-center, retrospective study of opioid-maintained 
patients (N = 77; 58% female, Mage = 54) certified to use medical cannabis for intractable pain in 
Michigian. Patients evinced a statistically-significant reduction in the median prescription opioid 




ratings was observed over the six month study. This study was imited such that patients were 
included only if they filled their medical cannabis certification (64%). Research is needed that 
can increase generalizability by conducting analyses in other states and among patients receiving 
their initial certification (O'Connell et al., 2019; Vigil et al., 2017). Furthermore, the relatively 
small sample size of both studies precluded the ability to test frequency/dosage of medical 
cannabis purchases in relation to changes in prescription opioid use, and examine variables 
potentially related to medication usage such as age and sex. This is important as males may 
experience greater cannabis-induced analgesia than females (Cooper & Haney, 2016), and older 
age has been associated with more consistent adherence to prescribed medications (Hertz, Unger, 
& Lustik, 2005; Rolnick, Pawloski, Hedblom, Asche, & Bruzek, 2013). 
The first objective of the current study was to characterize medical cannabis use in terms 
of dosage, type, and purchase frequency over the first six months following certification among a 
sample of treatment-seeking chronic pain patients. We hypothesized that at least 75% of patients 
would purchase medical cannabis at least once (i.e., primary adherence; Raebel, Schmittdiel, 
Karter, Konieczny, & Steiner, 2013). The second objective was to test for changes in prescription 
opioid use as a function of purchasing medical cannabis. We predicted that at least 50% of those 
who purchased medical cannabis would either discontinue or reduce their use of prescription 
opioids, and that the magnitude of reduction would be positively associated with medical 
cannabis purchases. The third objective was to test the hypothesis that greater age and male (vs. 
female) sex, would be positively associated with medical cannabis purchase frequency, as well 
as reductions in prescription opioid use among patients who purchased medical cannabis at least 
once. Finally, exploratory analyses were conducted to test the interaction of age and sex in terms 




terms of analgesic response (Britch, Goodman, Wiley, Pondelick, & Craft, 2020; Craft, Britch, 
Buzitis, & Clowers, 2019).  
Method 
 
Participants and Procedures 
Participants were patients seeking treatment at a tertiary outpatient pain clinic who 
presented for an initial medical cannabis certification. All procedures were approved by the 
Institutional Review Board of Syracuse University. An office visit with a licensed physician was 
required to confirm a diagnosis of chronic (non-cancer) pain prior to certification. Patients were 
then registered to use medical cannabis through the State. Finally, patients were instructed to 
schedule a separate appointment with one of the local dispensaries to purchase medical cannabis. 
Cannabis flower products are not permitted in New York State, otherwise patients have full 
discretion to self-manage the type, frequency, potency of medical cannabis they use. Patients are 
permitted to use medical cannabis in conjunction with other medical treatments including opioid 
pain medications. Patients are not provided instructions for altering opioid medications or other 
prescription medications while using medical cannabis. A follow-up period of six months was 
chosen based on theories of medication behavior change (Rottman, Marcum, Thorpe, & Gellad, 
2017), existing data among medical cannabis users (Zolotov et al., 2016), and is consistent with 
previous retrospective studies (O'Connell et al., 2019). 
Inclusion and Exclusion Criteria 
Inclusion criteria. The sample was limited by internal clinic guidelines which specify 
that patients seeking medical cannabis certification must be a current patient of the practice and 
seeking certification for chronic pain only, and not receiving medication assisted treatment 




opioid-based pain medication to treat chronic pain. Current federal law also prohibits patients 
from receiving workers compensation to pay out of pocket for healthcare expenses, including 
medical cannabis. Further, insurance companies do not currently consider medical cannabis to be 
a valid medical intervention. Thus, the current study is limited to patients who were not receiving 
workers compensation and able to pay out of pocket for the cost of the medical cannabis 
certification visit ($150.00 USD).  
Exclusion criteria. Patients were excluded if they left the clinic practice (i.e., moved), 
died, or were discharged for any reason during the study period (i.e., non-payment for services, 
lapse in insurance, disagreement with provider).  
Measures  
Demographic and visit data. Demographic data and dates of clinical visits were extracted 
from the Electronic Medical Record (EMR) for all patients who received an initial medical 
cannabis certification over one calendar year between 1/1/2018 and 12/31/2018.  
Medical Cannabis Data. Patient use of their medical cannabis certification was extracted 
from electronic medical records using New York State Prescription Drug Monitoring Program 
(PDMP) data indicating whether medical cannabis was purchased. Purchase(s) of medical 
cannabis during the six-month observation period (i.e., primary adherence) was dummy coded, 
where “0” represented that no medical cannabis was purchased, and “1” represented that medical 
cannabis was purchased at least once. Doses of medical cannabis were based on the 
recommended daily dose (RDD) for each product as determined by the licensed pharmacist at the 
dispensary. Purchase frequency was determined by summing each day that a purchase was made 
(only one visit is allowed per day). Active product at follow-up was operationalized as having 




Product formulations and administration methods were based on those required my NY State 
(e.g., THC:CBD ratios).  
Opioid Prescription Data. Prescription opioid data was extracted from the electronic 
medical record which is based on New York State PDMP data. Medication data was extracted at 
the time of medical cannabis certification, and at six months following certification (Bellnier, 
Brown, & Ortega, 2018; Simmonds, Finley, Vale, Pugh, & Turner, 2015). Two metrics were 
used to evaluate change in opioid consumption over time to be consistent with previous research 
(Vigil et al., 2017). First, dummy coding was accomplished by creating a dichotomous variable 
where “1” is defined as having filled any opioid prescription at the time of the six-month follow-
up, and “0” indicates that no prescription was filled. Second, a mean daily dose of prescription 
opioid medication in morphine milligram equivalents (MME) was calculated at time of 
certification and at six months post-certification. Consistent with previous research (Vigil et al., 
2017), dosages of opioid prescription(s) filled at both time points were aggregated after 
converting to morphine milligram equivalents based on CDC guidelines (Dowell, Haegerich, & 
Chou, 2016), and using the GLOBALRPh calculator.  
Pain Intensity. The Numerical Rating Scale (NRS; McCaffery & Beebe, 1989) was used 
to index pain intensity. Patients are asked to rate current pain intensity from 0 (no pain) to 10 
(pain as bad as you can imagine). The NRS has been used extensively to index pain in both 
research and clinical settings and has demonstrated excellent construct and discriminant validity 
(Hjermstad et al., 2011; Williamson & Hoggart, 2005). The current study used data from the 
medical cannabis certification visit and the office visit closest to the six-month follow-up. 




All analyses were conducted using SPSS Statistics 21 (IBM Corp, 2012), and the conduct 
and reporting of logistic regression models is based on recommended procedures (Moss, 
Wellman, & Cotsonis, 2003). The distributions of all continuous variables were examined for 
normality. Positive skewness was observed for morphine milligram equivalents at both baseline 
and follow-up (skew = 2.45 and 2.59, respectively), as well as frequency of purchasing medical 
cannabis (skew = 1.96). Recommended corrections were applied (i.e., log10; Tabachnick & 
Fidell, 2004), which resulted in a normalized distribution for all three variables (skew = 0.16, -
0.53, and -0.1, respectively). Analyses to evaluate mean difference among baseline variables and 
NRS pain scores between timepoints (i.e., t-tests) were calculated using a bootstrapped re-
sampling approach set at 5,000 resamples to generate 95% CIs. 
Inferential analyses were conducted with resampling using bootstrapping, an analytic 
approach which reduces limitations associated with statistical power and Type 1 error inherent to 
regression modeling. This approach is also recommended to reduce optimistic prediction errors 
in logistic regression (Smith, Seaman, Wood, Royston, & White, 2014). For both linear and 
logistic regression models, bootstrapping was set at 5,000 re-samples, and the PROCESS macro 
was employed for testing moderation (Preacher & Hayes, 2008). A maximum likelihood 
approach was used to evaluate the validity of the logistic regression models. Odds ratios, and 
Nagelkerke’s R2 values were used to evaluate the statistical significance and relative explanatory 
power of the logistic regression models. The Wald statistic was examined to estimate the 
contribution of each predictor. Linear regression models were based on an ordinary least-
squares-based approach, and statistical significance of each model was evaluated based on 




each predictor variable in explaining observed variance in each criterion variable were assessed 
by examining the R-squared statistic (R2).  
Results 
Participant Characteristics and Pain Ratings 
Participants included 277 patients with chronic pain (60.6% female; 90.6% 
White/Caucasian; 89.9% non-Hispanic/Latino; Mage = 56.3, SD = 13.2, Median = 58). Female 
patients were older than male patients; t(274) = 2.9, p = .005, 95% CI = 1.42:7.72 (female; M = 
58.1, SD = 13.4, male; M = 53.5, SD = 12.2). Most patients (51.3%) were using Medicare as 
their primary insurance. The most common pain location was in the lumbar and thoracic regions 
(87%), and patients reported a mean of two pain locations (M = 1.9; range 0-5). A diagnosis of 
pain with neuropathic features was present for most patients (79.4%). Pain intensity ratings 
(NRS) at the most recent pain clinic visit (M = 5.9, SD = 2.1) indicate that the sample was 
experiencing moderate and clinically significant pain (Krebs, Carey, & Weinberger, 2007). 
Paired samples t-test indicated no change in NRS ratings collected closest to date of certification 
(M = 5.93) vs. NRS ratings closest to the six-months follow-up (M = 5.66); t(234) = 1.81, p = 
.07, 95% CI = -0.03:0.56. See Tables 1 and 2 for sociodemographic and pain characteristics 
organized by use of medical cannabis. 
Characteristics of Medical Cannabis Purchases 
 Consistent with hypothesis, approximately 91% of the sample filled their certification for 
medical cannabis at least once by six months following initial certification (n = 253, 91.3%). 
Patients purchased medical cannabis using their certification a median of three separate times 




purchased medical cannabis at least once 45% had active product at follow-up. The most 
commonly purchased product in terms of method of administration was vaporization (61.3% of 
patients purchased at least once) and the least common method purchased was oral spray (32.8% 
purchased at least once). Product formulations containing low CBD and high THC content were 
the frequently purchased in terms of total doses (50.5%). See Table 3 for details of medical 
cannabis use. 
Changes in Prescription Opioid Use at Six Months Post-Certification 
The median aggregated dose of prescribed opioids was 44.3 MME at time of certification 
(mean = 47.4, range = 5:320). At six-month follow-up, the median aggregated dose of prescribed 
opioids was 20 MME (mean = 37.8, range = 0:320), representing an average decrease of 24% 
compared to the day of certification. Among those who purchased medical cannabis, 105 (42%) 
stopped or reduced their prescription opioid use during the first six months following 
certification, with a mean reduction of 22.8 MME/day (SD=66.4; range = 1.2 - 130). Among 
those who purchased medical cannabis, 38% achieved a clinically-significant reduction in opioid 
use during the study period (± 30%; Buonora, Perez, Heo, Cunningham, & Starrels, 2018; Henry, 
Wilsey, Melnikow, & Iosif, 2015), with (26%) of these patients discontinuing use. 
Changes in Prescription Opioid Use as a Function of Medical Cannabis Use 
Regression models indicated no association between filling a medical cannabis 
certification at least once, total medical cannabis purchases, or total dosages and the likelihood of 
stopping/reducing (vs. stable/increasing) prescription opioid use (ps > .05, 95% CIs ± 0). Follow-
up analyses indicated that nearly half (46%) of patients who purchased medical cannabis at or 




contrast, only 36% of patients who filled below the median number of times reduced or stopped 
their use of prescription opioids. This difference was not statistically significant (χ2 = 2.8; p = 
.09).  
Medical Cannabis Use and Changes in Prescription Opioids as a Function of Age and Sex 
In terms of the type of products used, female (vs. male) patients purchased greater daily 
doses of equal ratio THC:CBD products t(253) = 3.43, p = .001 95% CI = 4.07:15.05 (Female; 
M = 19.8, SD = 31.2, Male; M = 10.3, SD = 14.7). Neither age nor sex was associated with the 
odds of purchasing (vs. not purchasing) medical cannabis during the study period (ps > .05, 95% 
CIs ± 0), the total number of separate purchase instances period (ps > .05, 95% CIs ± 0), nor total 
dosages purchased during the study period (ps > .05, 95%CIs ±0). In terms of the likelihood of 
having an active product at follow-up, no differences were observed as a function of age or sex 
(ps > .05, 95%CIs ±0). However, an interaction effect was observed among those who purchased 
product at least once. Specifically, age was positively associated with greater log odds of having 
an active product at follow-up among males but not among females (χ2 = 8.7, df = 1, p < .01). 
Among those who purchased medical cannabis, neither age nor sex was associated with odds of 
stopping/reducing (vs. stable/increasing) prescription opioid use (ps > .05, 95%CIs ±0), or 
changes in daily MME (ps > .05, 95%CIs ±0). See tables 5 and 6 for details of regression 
models.  
Discussion 
The current study is the largest EMR and PDMP-based retrospective examination of 
medical cannabis and prescription opioid use among a sample of treatment-seeking chronic pain 




filled their medical cannabis certification at least once and nearly half (45%) had an active 
product at follow-up. The frequency of medical cannabis purchases was heterogenous, exhibited 
a positively skewed distribution, and a median of three transactions over the six-month study 
period. Among patients who purchased medical cannabis, 42% reduced their prescription opioid 
use by six months post-certification with 26% of these patients discontinuing use entirely. The 
proportion of opioid reduction/elimination was 10% greater among patients who purchased 
medical cannabis at least three times (vs.< 3 times). Female (vs. male) patients purchased greater 
dosages of equal ratio THC:CBD products, and age was positively associated with greater odds 
of having an active product at follow-up among males but not among females. Contrary to 
hypotheses, no further associations were observed between age, sex, or other indices of medical 
cannabis consumption, nor subsequent changes in prescription opioid use.  
The majority of patients in the current study (91%) purchased medical cannabis at least 
once. This is 27% higher than observed in another cohort of chronic pain patients that also used a 
six month observation period (O'Connell et al., 2019), which could be a result of numerous 
factors including sampling criteria (i.e., co-use of benzodiazepines; O’Connell et al, 2019). The 
frequency of purchases was positively skewed (skew = 1.96) and patients purchased a wide 
range of dosage days (range = 5:417, mean = 64.5, SD = 67.2). Heterogeneity in medication use 
can be influenced by a variety of factors, including complexity of the medication regimen/lack of 
patient education, lack of efficacy/unfavorable side-effects, as well as cost (Fishman et al., 
2000). Thus, at least three interrelated reasons may explain current findings. First, unlike 
prescription medications the dosing, timing of use, and method of administration is not 
standardized for medical cannabis (Brooks, Gundersen, Flynn, Brooks-Russell, & Bull, 2017; 




general diagnostic considerations (i.e., chronic pain) and not product variables (Kansagara, 
Becker, Ayers, & Tetrault, 2019). In the absence of specific guidance from providers, patients 
may rely on dispensary staff for advice. For example, only 2.6% of medical cannabis patients 
choose products based on advice from a medical professional and about half rely on dispensary 
employees (54.9%; Boehnke, Scott, Litinas, Sisley, Clauw, et al., 2019), who do not always 
provide evidence-based recommendations (Haug et al., 2016). 
Second, inconsistency in the effects of cannabinoids and possible side effects might have 
contributed to the heterogenous pattern of use observed here (Lotsch, Weyer-Menkhoff, & 
Tegeder, 2018; Mun et al., 2020). For example, patients may trial multiple products in an attempt 
to titrate dosing to meet the narrow therapeutic window for analgesic effects (Khan, Pickens, & 
Berlau, 2019; Wallace et al., 2007). Presence of side-effects may also have driven some patients 
to discontinue use. Indeed, high THC:low CBD formulations were the most commonly 
purchased in the current sample (M = 41 dosage days), and unwanted side-effects are most 
common with high THC products (Martin-Sanchez, Furukawa, Taylor, & Martin, 2009). Third, 
the cost of medical cannabis may have led patients to use less than needed for adequate efficacy 
or have led some to ration their dosing (O'Connell et al., 2019). Medical cannabis patients spend 
a mean of over $3,000 per year on these products (Piper et al., 2017), and almost 30% of 
dispensary patients with chronic pain cite cost as a problem (Piper et al., 2017). The expense 
associated with medical cannabis has been hypothesized as a reason that nearly half of medical 
cannabis patients in Minnesota did not re-enroll in the program (Philbrick, 2019).  
Vaporization-based products were the most purchased method of administration among 
the current sample. One possible explanation for this finding is that vaporization allows patients 




(Shiplo, Asbridge, Leatherdale, & Hammond, 2016). Vaporized products also produce a more 
robust analgesic response compared to tinctures and edibles (Mun et al., 2020). Furthermore, 
recent findings indicate that non-inhalation-based products from licensed dispensaries often do 
not contain the advertised amounts of active ingredients (i.e., CBD, THC; Vandrey et al., 2015). 
Despite these potential advantages of vaporized products, other methods of administration (i.e., 
tinctures, edibles) were purchased by 33% to 55% of patients in the current study. These patients 
may have prioritized avoiding the potential health risks associated with inhalation-based 
products (Fischer et al., 2017a). Indeed, even non-combustible vaporization confers possible 
health problems (Fischer et al., 2017a). Most notably, incidences of e-cigarette or vaping 
associated lung injury (EVALI) have been associated with use of THC-containing vape products 
(Moritz et al., 2019), perhaps a result of contamination with vitamin E acetate (Blount et al., 
2019).  
Regarding changes in opioid use, nearly half (42%) of all patients reduced or stopped 
filling their opioid prescriptions during the study period. Furthermore, nearly 40% of patients 
reached a clinically significant decrease in prescription opioid dosage as defined by ≥ 30% MME 
reduction (Buonora et al., 2018; Henry et al., 2015). This is the first study to test for differences 
in opioid reduction between those who purchased (vs. did not purchase) medical cannabis. Both 
groups evinced a reduction in prescription opioid use (42% vs. 46%, respectively). This 
difference was not statistically significant, yet an unexpectedly small number of patients did not 
purchase medical cannabis (n = 24). Given the small sample of non-users and the positive skew 
of medical cannabis purchase frequency, further analysis was conducted based on median 
purchase frequency. These analyses revealed that patients who purchased medical cannabis 




elimination. This is a novel finding as previous studies have not tested for a relationship between 
medical cannabis purchases and changes in prescription opioid use (Vigil et al., 2017). This 
signal, albeit it limited, could be reflective of a dose-response relationship between medical 
cannabis use and prescription opioid use.  
In terms of changes in prescription opioid use, a few differences were observed compared 
to previous retrospective studies (O'Connell et al., 2019; Vigil et al., 2017). Vigil et al. (2017) 
reported a higher percentage of prescription opioid reduction (84%) and discontinuation (40%) 
compared to the current study (42% and 26%, respectively). One possible explanation is that the 
longer follow-up period of 21 months captured pateints who took longer to titrate down their 
prescription opioids (Vigil et al., 2017). Indeed, O’Connell et al. (2019) reported that no patients 
discontinued prescription opioid use by six months post-medical cannabis certification, despite a 
statistically significant reduction in total opioid dosage (O'Connell et al., 2019). No change in 
NRS pain ratings was observed between time of certification and six months post-certification in 
the present study, which is consistent with prior findings and suggests analgesic response was 
maintained (O'Connell et al., 2019). However, a second study reported a statistically significant 
reduction in NRS ratings at 12 months post-certification (Vigil et al., 2017). One posssible 
explanation for these findings is that a reduction in opioids is more likley with lower initial 
doses, which are perhaps reflective of less severe pain. Indeed, medical cannabis users in the 
current study were prescribed higher mean doses of opioids at time of certification (47 MME) 
compared to the study that observed a reduction in NRS scores (24 MME; Vigil et al., 2017). 
One method to compare samples maintained on varying doses of prescription opioids is to test 
for the clinical signifigance of opioid dose reduction, which is typically defined as ≥ 30% MME 




reduction in opioid dosage, which reflects the majority of patients who reduced/discontinued at 
all. This is especially notable given that prescription opioid dosing is often stable over time 
among chronic pain patients (Henry et al., 2015). 
Collectively, it appears that a portion of medical cannabis patients may evince clinically 
significant reductions in prescription opioid use after initiating medical cannabis, without 
reporting a change in pain intensity. One tentative possibility is that this reflects the opioid-
sparing effects seen in experimental studies (Chen et al., 2019; Nielsen et al., 2017). Regardless 
of the specific mechanism involved, reductions in prescription opioids following medical 
cannabis use could mitigate risk of deadly overdose (Guy et al., 2017) and decrease both the 
frequency and severity of side effects that are common with chronic administration of opioids 
(Anastassopoulos et al., 2013).  
In terms of age and sex distribution, the mean age of the current sample was 56.3 and 
skewed female (60% female), which is broadly consistent with previous studies (Degenhardt et 
al., 2015; O'Connell et al., 2019; Vigil et al., 2017). Female (vs. male) patients purchased greater 
total daily dosages of high CBD:low THC products, and age was positively associated with 
greater log odds of having an active medical cannabis product at follow-up among males but not 
among females. Contrary to hypotheses, no further age or sex differences were observed in terms 
of medical cannabis use or changes in prescription opioid dosage. These hypotheses were based 
on theories of prescription medication use (Rottman et al., 2017) and findings often among 
patients using cannabis for therapeutic purposes without a certification (e.g., Cuttler, Mischley, 
& Sexton, 2016). Thus, one possibility that hypotheses were not supported is that the 
relationships typically observed for prescribed medication do not generalize to medical cannabis 




certification (Pedersen, Tucker, Seelam, Rodriguez, & D'Amico, 2019) and have prior 
experience with cannabis (Cooper & Craft, 2018). On the other hand, meta-analysis indicates 
that women (vs. men) are more likely to use prescription opioids (Serdarevic, Striley, & Cottler, 
2017). Thus, one tentative explanation for current findings is that males experience with 
cannabis translates to a more typical pattern of medication taking behavior. The interaction 
between age and sex is suggested by initial experimental research (Britch et al., 2020; Craft et 
al., 2019) but more research is required to confirm current results.  
The present study raises several clinical implications. First, providers might consider 
ongoing monitoring of medical cannabis patients’ motivation and intention to reduce their 
prescription opioids for at least six months following initial certification. Early identification and 
support for patients who are trying to reduce their use of prescription opioids could help mitigate 
iatrogenic effects of prescription opioids (Darnall, Mackey, et al., 2019). Importantly, such a 
patient-centered approach must also consider the potential benefits of prescription opioids and 
avoid forced tapering of these medications (Darnall, et al., 2019; Darnall et al., 2018). Second, 
providers might consider ways to reduce the overall cost of medical cannabis, perhaps by 
minimizing certification fees for the large proportion of patients on a fixed income (i.e., use of 
Medicare/Medicaid). Indeed, 61% of the current sample was covered primarily by a government 
funded insurance program. Helping patients afford adequate dosing of medical cannabis could 
mitigate wasted financial resources and reduce the burden on healthcare systems (Briesacher, 
Gurwitz, & Soumerai, 2007).  
Third, providers might consider ongoing use of state prescription drug monitoring 
systems to monitor adherence and identify increases in use which might suggest development of 




& Craft, 2014). Tracking patient’s use of medical cannabis might also be used to improve 
patient-centered care by reinforcing treatment goals (Moore et al., 2004). For example, 
personalized feedback using data from drug monitoring programs and delivered using a 
motivational enhancement therapy (MET) approach might facilitate accurate perceptions of 
medication effects and improve adherence (Palacio et al., 2016; Rottman et al., 2017).  
Fourth, mixed findings with regard to age and sex indicate the need for further tests to 
identify predictors of medical cannabis utilization (Gast & Mathes, 2019), and dissuade 
providers from generalizing findings from prescription medication use to medical cannabis 
(Kansagara et al., 2019). For example, common co-morbid psychiatric problems among those 
with chronic pain such as depression and anxiety-related disorders (Feingold, Brill, Goor-Aryeh, 
Delayahu, & Lev-Ran, 2017; Hooten, 2016) may evince nonintuitive relationships to medical 
cannabis use. Indeed, recent meta-analysis indicates that anxiety (50%), and depression/mood 
(34%) are common reasons for medical cannabis use (Kosiba, Maisto, & Ditre, 2019), yet 
chronic exposure to cannabis may exacerbate certain psychiatric symptoms (National Academies 
of Sciences, 2017). Taken together, an idiographic approach to the use of medical cannabis 
comprised of substantial patient education, collaboration, and monitoring of treatment goals 
seems warranted (Beaulieu, Boulanger, Desroches, & Clark, 2016; Kahan et al., 2014; 
MacCallum & Russo, 2018; Sutherland, Nicholls, & Clarke, 2017). Theoretical models of 
medication adherence posit that patients rely on beliefs derived from initial personal experiences 
with medications to make decisions regarding their use in pursuit of a desired health outcome 
(Rottman et al., 2017). Thus, any additional support from providers may be especially impactful 




The current study follows calls for examining associations between medical cannabis and 
opioid use among individuals with chronic non-cancer pain (Brooks et al., 2017; Carlini, Garrett, 
& Carter, 2017; Hill, Palastro, Johnson, & Ditre, 2017; St-Amant, Ware, Julien, & Lacasse, 
2015) and has several strengths. First, the use of a venue-based sample is a recommended 
approach that allowed for the recruitment of a highly specific population of critical interest 
(Rothman, Gallacher, & Hatch, 2013; Thomas & Freisthler, 2016). This approach also builds on 
studies among online convenience samples (Bonn-Miller, Boden, Bucossi, & Babson, 2014), 
which are often biased representations of the larger population (Jeong et al., 2019). The use of a 
retrospective design is also a recommended approach to studying relationships between medical 
cannabis and prescription opioids (McCarty, 2018), as it minimizes potential for provider bias in 
prescribing practices associated with a prospective design (Verheij, Curcin, Delaney, & 
McGilchrist, 2018). The current study also extends prior self-report studies (e.g., Boehnke et al., 
2016) by including objective data on opioid and medical cannabis purchases. This helps to 
minimize reporting bias and loss of follow-up, which have been as high as 60% in previous 
samples (Vigil, Stith, & Reeve, 2018; Zolotov et al., 2016). Lastly, this is the first study to 
examine age and sex in relation to medical cannabis use and subsequent prescription opioid use.  
The current results must be interpreted in the context of specific methodological 
limitations. First, while the retrospective design extends previous cross-sectional research, no 
causal relationships can be inferred. Future research might use a control group matched on key 
variables that would be prohibited in randomized experimental designs (i.e., length of opioid use; 
Scherrer & Pace, 2017). Second, the current study did not collect data on the concomitant use of 
cannabis obtained without a certification, use of cannabis for non-therapeutic purposes, 




period. Use of non-medical cannabis is one possible explanation for the changes in prescription 
opioid use observed among those who did not purchase medical cannabis. Thus, research is 
needed to examine these variables as potential confounds and modifiers of observed associations. 
Third, the current study used a single follow-up interval of six months, which was chosen to be 
consistent with theories of medication behavior change (Rottman et al., 2017), existing data 
among medical cannabis users (Zolotov et al., 2016), and to facilitate comparison across other 
studies (O'Connell et al., 2019; Vigil et al., 2017). However, reductions in MME may not be 
fully realized until up to 12 months following certification (Vigil et al., 2017)..  
Fourth, the current study did not examine core elements of co-occurring psychiatric 
disorders (i.e., transdiagnostic factors) that might influence medical cannabis use and subsequent 
changes in prescription opioids. For example, discomfort intolerance has been positively 
associated with cannabis use among persons with chronic pain (Kosiba, Mitzel, Zale, Zvolensky, 
& Ditre, 2020), and both distress (in)tolerance and pain-related anxiety have been associated 
with prescription opioid misuse among those with chronic pain (LaRowe et al., 2018; McHugh et 
al., 2016). Future research might also examine coping motives for medical cannabis use (K. M. 
Bohnert et al., 2018), expectancies for drug effects (Metrik et al., 2009), and the role of co-
morbid psychological disorders (Demyttenaere et al., 2007). For example, research is needed that 
assesses whether or not patients are motivated to reduce their prescription opioid use prior to the 
initiation of medical cannabis.  
Studies are needed which can examine the course of changes in medical cannabis use and 
prescription opioid use at multiple time points and over a longer follow-up period (i.e., ≥ 12 
months). The use of a venue-based sample has been recommended for studying medical cannabis 




geographic/legislative regions. A sampling strategy that makes use of multi-level modeling could 
test for different patterns of medical cannabis and prescription opioid use across treatment 
facilities nested within geographic regions (Keyes et al., 2016). Indeed, rapidly evolving 
legislation governing the use of medical cannabis has resulted in substantial geographic 
differences in the legality, availability, and acceptance of medical cannabis (Klieger et al., 2017). 
Future studies must keep up with these changes to produce timely, clinically relevant findings 
(Frieden, 2017; Ware, 2018).  
This retrospective study is an essential first step in a programmatic line of research aimed 
at improving our understanding of medical cannabis and prescription opioid use among chronic 
pain patients. Most patients (91%) purchased medical cannabis at least once within the first six 
months following certification. Clinically significant reductions in prescription opioid use were 
observed among 37% of those who purchased medical cannabis, despite substantial variability in 
products and dosages purchased. Future research is needed to test the possible role of 







































Potential Patients Identified via 
Automated Data Query 
(N = 297) 
Excluded via Study Eligibility Criteria 
o Age < 18 at baseline (n = 0) 
o No active prescription opioid use at 
baseline (n = 16) 
o No chronic pain diagnosis (n = 0) 
o Died during study period (n = 2) 
o Discharged/violated controlled 
substance consent agreement (n = 0) 
o Left practice during study period (n = 2) 
o Moved (n = 1) 
o Not documented (n = 1) 
Eligible for Current Study 
(N = 277) 
 
Potential Patients with Records 
Available 
(N = 297) 
Excluded via Records/System Factors 
o No records in PMP  (n = 0) 














(n = 24) 
Entire Sample  
(N = 277) 
 n (%) n (%) n (%) 
Biological Sex    
 Female 156 (61.7) 12 (50) 168 (60.6) 
 Male 97 (38.3) 12 (50) 109 (39.4) 
Ethnicity    
 Hispanic/Latino 4 (1.6) 2 (8.3) 6 (2.2) 
 Non-Hispanic/Latino 228 (90.1) 21 (87.5) 249 (89.9) 
 Declined to report 21 (8.3) 1 (4.2) 22 (7.9) 
Race    
 White 228 (90.1) 23 (95.8) 251 (90.6) 
 Black/African American 6 (2.4) 0 (0) 6 (2.2) 
 Asian 0 (0) 0 (0) 0 (0) 
 American Indian/Alaskan Native 1 (0.4) 0 (0) 1 (0.4) 
 Hawaiian/Pacific Islander 0 (0) 0 (0) 0 (0) 
 More than one Race 9 (3.6) 0 (0) 9 (3.2) 
 Declined to report 9 (3.6) 1 (4.2) 10 (3.6) 
Marital Status    
 Single 51 (20.2) 6 (25) 57 (20.6) 
 Married 151 (59.7) 12 (50) 163 (58.8) 
 Divorced 18 (7.1) 1 (4.2) 19 (6.9) 
 Widowed 3 (1.2) 1 (4.2) 4 (1.4) 
 Not documented or not reported 30 (11.9) 4 (16.7) 34 (12.3) 
Primary Insurance1    
 Private  97 (40.3) 5 (21.7) 102 (38.8) 
 Medicare 123 (51.2) 12 (52.2) 135 (51.3) 
 Medicaid 20 (8.3) 6 (26.1) 26 (9.9) 























Pain Locations, Pain Diagnoses, and Pain Intensity 
 
 Purchased Medical 
Cannabis 
 (n = 253)      
No Medical 
Cannabis Purchased 
(n = 24) 
Entire Sample 
(N = 277) 
 n (%) n (%) n (%) 
Pain Locations1    
 Head/Cervical 118 (46.6) 10 (41.7) 128 (46.2) 
 Back (Lumbar and Thoracic)  220 (87) 21 (87.5) 241 (87.0) 
 Lower Extremity  94 (37.2) 5 (20.8) 99 (35.7) 
 Upper Extremity 48 (19) 3 (12.5) 51 (18.4) 
 Chest 3 (1.2) 0 (0) 3 (1.1) 
 Stomach 1.4 (5.5) 0 (0) 14 (5.1) 
Pain Quality and Diagnoses1    
 Nerve Involvement/Nerve Pain 202 (79.8) 18 (75) 220 (79.4) 
 Fibromyalgia 22 (8.7) 1 (4.2) 23 (8.3)  
 Chronic Regional Pain Syndrome  5 (2) 0 (0) 5 (1.8) 












Pain Intensity2    












Note. 1Active clinical diagnosis/conditions recorded in the electronic medical record, Patients may have had 
multiple diagnoses; 2numerical rating scale for pain intensity.3Based on appointment data recorded ≤ date of 
















Medical Cannabis Use1 
 
Method of Administration Purchased 
Number of patients  
n (%) 
 Vaporizer 155 (61.3) 
 Tincture 139 (54.9) 
 Oral Spray 83 (32.8) 
 Capsules/Powder 117 (46.2) 
Active product at six months post-certification  113 (44.7) 
Type of Product  
Dosage days purchased 
M (SD) Range 
 High CBD and Low THC 5.5 (14.2) 0 – 106 
 Equal Ratio CBD and THC 17.5 (27) 0 - 150 
 Low CBD and High THC 41.4 (50.5) 0 – 292 
Aggregated Purchase Data M (SD) Range 
Number of separate days purchased  4.16 (3.19) 1 - 20 
Total dosages purchased  64.5 (67.25) 5 - 417 
  


















Prescription Opioid Dosages at Certification and Six-Months Post-Certification  
 Purchased Medical 
Cannabis 
 (n = 253)      
No Medical 
Cannabis Purchased 
(n = 24) 
Entire Sample 
(N = 277) 
 M (SD) M (SD) M (SD) 
At certification date 49.69 (74.29) 47.16 (45.32) 47.38 (48.34) 
At six-month follow-up 40.62 (75.37) 37.56 (45.37) 37.82 (48.52) 
Mean change in MME -9.06 (15.89) -9.6 (27.3) -9.55 (26.49) 
Mean % change in MME -34.3 (49.77) -22.85 (66.45) -23.85 (65.18) 






















Variables Associated with Medical Cannabis Use: Dichotomous Criterion 
 
 Criterion: Purchased medical cannabis (yes/no) 
 R2 β SE Wald’s χ2 95% CI p 
Age 0.00 -0.01 0.02 0.43 -0.05:0.03 .51 
Sex 0.01 -0.47 0.45 1.20 -1.38:0.43 .27 
Pain Intensity1 0.01 -0.1 0.13 0.97 -0.38:0.13 .4 
 Criterion: Active medical cannabis at follow-up (yes/no) 
 R2 β SE Wald’s χ2 95% CI p 
Age 0.02 0.02 0.01 3.52 -0.003:0.04 .07 
Sex 0.00 -0.05 0.25 0.04 -0.55:0.45 .85 
Pain Intensity1 0.02 -0.11 0.06 3.63 -0.23:0.004 .05 





































Path  Coeff. SE z p 95% CI 
Constant c -0.11 0.69 -0.16 .87 -1.48:1.25 
Age (X) b1 -0.00 0.01 -0.33 .73 -0.03:0.02 
Sex (M) b2 -3.81 1.26 -3.01 < .01 -6.29:-1.33 
Age x Sex (X*M) b3 0.07 0.02 3.11 < .01 0.02:0.11 





Variables Associated with Medical Cannabis Use: Linear Criterion 
 
 Criterion: Total daily doses of medical cannabis purchased  
 β b (SE) R2 95% CI t (p) 
Age 0.09 0.00 (0.00) 0.01 -0.00:0.01 1.38 (.17) 
Sex -0.02 -0.02 (0.06) 0.00 -0.13:0.09 -0.32 (.75) 
Pain Intensity1 -0.04 -0.01 (0.01) 0.00 -0.04:0.02 -0.68 (.49) 
 Criterion: Number of times medical cannabis was purchased 
 β b (SE) R2 95% CI t (p) 
Age 0.08 0.00 (0.00) 0.01 -0.00:0.00 1.3 (.2) 
Sex -0.01 -0.01 (0.03) 0.00 -0.06:0.06 -0.15 (.88) 
Pain Intensity1 -0.02 -0.00 (0.01) 0.00 -0.02:0.01 -0.34 (.73) 















Variables Associated with Prescription Opioid Use: Dichotomous Criterion  
 Criterion: Reduced prescription opioid use (yes/no) 
 R2 β SE Wald’s χ2 95% CI p 
Cannabis Purchases1 0.00 0.03 0.04 0.84 -0.04:0.1 .36 
Cannabis Dosage2 0.00 0.02 0.27 0.49 -0.36:0.79 .5 
Age 0.00 0.00 0.01 0.19 0.99:1.02 .67 
Sex 0.00 -0.19 0.26 0.55 -0.73:0.3 .46 
Pain Intensity3 0.01 -0.06 0.06 1.22 -0.18:0.05 .26 

















Variables Associated with Prescription Opioid Use: Linear Criterion  
 Criterion: Raw change in MME  
 β b (SE) R2 95% CI t (p) 
Cannabis Purchases1 -8.18 -8.18 (6.73) 0.01 -21.17:5.08 -1.2 (.23) 
Cannabis Dosage2 -0.05 -3 (3.54) 0.001 -9.96:3.91 -0.83 (.41) 
Age -0.04 -.08 (0.12) 0.001 -0.31:0.15 -0.59 (.55) 
Sex 0.1 5.54 (3.44) 0.01 -1.38:12.3 1.63 (.12) 
Pain Intensity3 0.07 0.88 (0.78) 0.005 -0.64:2.42 1.1 (.27) 
 Criterion: Percentage change in MME 
 β b (SE) R2 95% CI t (p) 
Cannabis Purchases1 -0.02 -5.5 (14.9) 0.00 -35.33:23.1 -3.2 (.75) 
Cannabis Dosage2 0.00 0.65 (8.5) 0.00 -16.86:16.58 0.07 (.94) 
Age 0.02 0.10 (0.003) 0.00 -0.52:0.77 0.3 (.76) 
Sex -0.01 -1.88 (9.23) 0.00 -19.21:17.2 -0.22 (.83) 
Pain Intensity3 0.11 3.47 (1.67) 0.01 0.3:6.86 1.73 (.09) 
Note. Sex: 0 = male, 1 = female; 1total number of medical cannabis purchases; 2total dosages 













Morphine Milligram Equivalents (MME) Calculations1 
Opioid (in mg/day except as noted) Conversion Factor 
Codeine 0.15 





≤ 20 = 4 
> 20, ≤ 40 = 8 
> 40, ≤ 60 = 10 
















Numerical Rating Scale for Pain (NRS) 
How would you rate your pain RIGHT NOW? 
No Pain        
Pain as bad 
as could be 
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